Zimmer Biomet Holdings Inc
NYSE:ZBH
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Zimmer Biomet Holdings Inc
NYSE:ZBH
|
17.2B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
128.4B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.6B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
183.1B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
169.7B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
103B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.9B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
41.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.9B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
32.9B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Zimmer Biomet Holdings Inc
Glance View
Zimmer Biomet Holdings Inc. stands as a prominent player in the medical device industry, specializing in musculoskeletal healthcare. Emerging from a rich legacy that dates back to its origins in the early 20th century, the company has carved out its niche by innovating in the orthopedic reconstruction sector. Zimmer Biomet operates primarily through designing, manufacturing, and marketing a comprehensive range of orthopedic products, which include joint replacement implants, such as knees, hips, and shoulders, as well as products used for fracture fixation and bone growth stimulation. The innovative edge of Zimmer Biomet lies in its commitment to improving patient outcomes and enhancing the quality of life through advanced surgical and robotic technologies. The company invests significantly in R&D to maintain its competitive edge, constantly pushing the boundaries in personalized solutions and minimally invasive surgery. The company generates revenue by selling its orthopedic and surgical products directly to hospitals, surgical centers, and healthcare providers worldwide. Zimmer Biomet's business model is heavily reliant on the relationships it builds with orthopedic surgeons and healthcare institutions, positioning itself as an essential partner in delivering sophisticated solutions for musculoskeletal health. By focusing on comprehensive, integrated solutions, Zimmer Biomet not only addresses the immediate surgical needs but also engages with the continuum of care in rehabilitation and patient recovery. The company’s strategic acquisitions, sophisticated product pipeline, and global market presence enable it to capture a significant share of the medical device market, ensuring its role as a stalwart in transforming the future of healthcare.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Zimmer Biomet Holdings Inc is 8.6%, which is below its 3-year median of 10.6%.
Over the last 3 years, Zimmer Biomet Holdings Inc’s Net Margin has increased from 3.3% to 8.6%. During this period, it reached a low of 3.3% on Dec 31, 2022 and a high of 14.3% on Sep 30, 2024.